Recently, Tai’ai Peptide Group was awarded the 2024 “No. 1 in National Sales of Bovine Collagen Peptides” market position certificate for its outstanding performance in the market in 2024. The certificate was issued by Huaxinren (Beijing) Information Consulting Co., Ltd.
Based on the omnichannel sales volume (in tons) of various brands of bovine bone collagen peptide powder in the national (excluding Hong Kong, Macao, and Taiwan) retail market in 2024. Bovine bone collagen peptide powder is a powdered product primarily composed of oligopeptides (short peptides) with a relative molecular mass of less than 1000 u, produced enzymatically from fresh bovine bones (with or without the addition of citric acid and flavorings). The survey was completed in August 2025.
Deeply cultivating the peptide field to establish industry status
Since its inception, Tai’ai Peptide Group has consistently focused on research, innovation, and industrial development in the peptide field, accumulating a rich legacy of 28 years. This honor stems from Tai’ai Peptide Group’s unwavering commitment to quality as its core value. Leveraging bio-enzymatic hydrolysis technology, the Group has established a comprehensive industry chain control system, encompassing raw material selection, process innovation, and quality testing, ensuring each batch of products is pure, active, and safe.
In addition to exceptional product quality, Tai’ai Peptide Group has also achieved fruitful results in the translation of scientific research findings. The Group collaborates closely with major domestic universities to conduct clinical trials, resulting in over 300 scientific discoveries and successfully applying cutting-edge research theories to product development and production practices. This deep integration of industry, academia, and research enables Tai’ai Peptide Group to continuously launch high-quality products that meet market demand and lead industry development.
Market sales are the ultimate criterion for evaluating product value. The release of this authoritative data by Huaxinren (Beijing) Information Consulting Co., Ltd. not only fully affirms Taiai Peptide Group’s industry leadership but also lays the foundation for the high-quality development of the entire peptide health industry. Going forward, Taiai Peptide Group will continue to uphold the principles of technological innovation, continuously enhance its product and service experience, support the implementation of the “Healthy China” strategy, and contribute its expertise to the health of the nation.
Post time: Aug-27-2025